Annual EBITDA
-$11.17 M
+$1.06 M+8.70%
December 1, 2023
Summary
- As of February 10, 2025, NRSN annual EBITDA is -$11.17 million, with the most recent change of +$1.06 million (+8.70%) on December 1, 2023.
- During the last 3 years, NRSN annual EBITDA has fallen by -$8.35 million (-295.47%).
- NRSN annual EBITDA is now -804.62% below its all-time high of -$1.24 million, reached on December 31, 2019.
Performance
NRSN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$2.11 M
+$923.00 K+30.46%
September 1, 2024
Summary
- As of February 10, 2025, NRSN quarterly EBITDA is -$2.11 million, with the most recent change of +$923.00 thousand (+30.46%) on September 1, 2024.
- Over the past year, NRSN quarterly EBITDA has increased by +$887.00 thousand (+29.63%).
- NRSN quarterly EBITDA is now -1965.69% below its all-time high of -$102.00 thousand, reached on December 1, 2021.
Performance
NRSN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$10.41 M
+$519.00 K+4.75%
September 1, 2024
Summary
- As of February 10, 2025, NRSN TTM EBITDA is -$10.41 million, with the most recent change of +$519.00 thousand (+4.75%) on September 1, 2024.
- Over the past year, NRSN TTM EBITDA has increased by +$859.00 thousand (+7.62%).
- NRSN TTM EBITDA is now -393.27% below its all-time high of -$2.11 million, reached on March 1, 2021.
Performance
NRSN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NRSN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.7% | +29.6% | +7.6% |
| 3 y3 years | -295.5% | +39.7% | -45.1% |
| 5 y5 years | -804.6% | +0.2% | -393.3% |
NRSN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -176.7% | +8.7% | -1965.7% | +39.7% | -157.7% | +17.5% |
| 5 y | 5-year | -804.6% | +8.7% | -1965.7% | +39.7% | -393.3% | +17.5% |
| alltime | all time | -804.6% | +8.7% | -1965.7% | +39.7% | -393.3% | +17.5% |
NeuroSense Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.11 M(-30.5%) | -$10.41 M(-4.7%) |
| Jun 2024 | - | -$3.03 M(+1.2%) | -$10.93 M(-3.0%) |
| Mar 2024 | - | -$2.99 M(+31.2%) | -$11.27 M(+0.0%) |
| Dec 2023 | -$11.17 M(-8.7%) | -$2.28 M(-13.1%) | -$11.27 M(-7.6%) |
| Sep 2023 | - | -$2.63 M(-22.1%) | -$12.19 M(-2.5%) |
| Jun 2023 | - | -$3.37 M(+12.7%) | -$12.50 M(-1.0%) |
| Mar 2023 | - | -$2.99 M(-6.6%) | -$12.62 M(+2.4%) |
| Dec 2022 | -$12.24 M | -$3.20 M(+9.2%) | -$12.32 M(+33.6%) |
| Sep 2022 | - | -$2.93 M(-16.1%) | -$9.22 M(+28.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$3.50 M(+29.9%) | -$7.18 M(+55.3%) |
| Mar 2022 | - | -$2.69 M(+2539.2%) | -$4.62 M(+14.4%) |
| Dec 2021 | -$4.04 M(+42.9%) | - | - |
| Dec 2021 | - | -$102.00 K(-88.5%) | -$4.04 M(+2.6%) |
| Sep 2021 | - | -$888.00 K(-5.5%) | -$3.94 M(+29.1%) |
| Jun 2021 | - | -$940.00 K(-55.5%) | -$3.05 M(+44.5%) |
| Mar 2021 | - | -$2.11 M | -$2.11 M |
| Dec 2020 | -$2.83 M(+128.7%) | - | - |
| Dec 2019 | -$1.24 M | - | - |
FAQ
- What is NeuroSense Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for NeuroSense Therapeutics?
- What is NeuroSense Therapeutics annual EBITDA year-on-year change?
- What is NeuroSense Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for NeuroSense Therapeutics?
- What is NeuroSense Therapeutics quarterly EBITDA year-on-year change?
- What is NeuroSense Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for NeuroSense Therapeutics?
- What is NeuroSense Therapeutics TTM EBITDA year-on-year change?
What is NeuroSense Therapeutics annual EBITDA?
The current annual EBITDA of NRSN is -$11.17 M
What is the all time high annual EBITDA for NeuroSense Therapeutics?
NeuroSense Therapeutics all-time high annual EBITDA is -$1.24 M
What is NeuroSense Therapeutics annual EBITDA year-on-year change?
Over the past year, NRSN annual EBITDA has changed by +$1.06 M (+8.70%)
What is NeuroSense Therapeutics quarterly EBITDA?
The current quarterly EBITDA of NRSN is -$2.11 M
What is the all time high quarterly EBITDA for NeuroSense Therapeutics?
NeuroSense Therapeutics all-time high quarterly EBITDA is -$102.00 K
What is NeuroSense Therapeutics quarterly EBITDA year-on-year change?
Over the past year, NRSN quarterly EBITDA has changed by +$887.00 K (+29.63%)
What is NeuroSense Therapeutics TTM EBITDA?
The current TTM EBITDA of NRSN is -$10.41 M
What is the all time high TTM EBITDA for NeuroSense Therapeutics?
NeuroSense Therapeutics all-time high TTM EBITDA is -$2.11 M
What is NeuroSense Therapeutics TTM EBITDA year-on-year change?
Over the past year, NRSN TTM EBITDA has changed by +$859.00 K (+7.62%)